Wells Fargo’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-31
Closed -$18 7781
2023
Q1
$18 Buy
31
+1
+3% +$1 ﹤0.01% 7400
2022
Q4
$21 Buy
30
+1
+3% +$2 ﹤0.01% 7278
2022
Q3
$0 Sell
29
-7
-19% -$26 ﹤0.01% 7761
2022
Q2
$0 Buy
36
+4
+13% +$18 ﹤0.01% 7857
2022
Q1
$0 Hold
32
﹤0.01% 8174
2021
Q4
$0 Hold
32
﹤0.01% 8101
2021
Q3
$0 Sell
32
-6
-16% -$83 ﹤0.01% 7778
2021
Q2
$1K Buy
38
+23
+153% +$429 ﹤0.01% 6798
2021
Q1
$0 Buy
15
+10
+200% +$253 ﹤0.01% 7614
2020
Q4
$0 Buy
5
+2
+67% +$30 ﹤0.01% 7256
2020
Q3
$0 Sell
3
-399
-99% -$7.5K ﹤0.01% 7141
2020
Q2
$6K Hold
402
﹤0.01% 5952
2020
Q1
$5K Buy
402
+2
+0.5% +$41 ﹤0.01% 5872
2019
Q4
$12K Buy
400
+393
+5,614% +$9.4K ﹤0.01% 5865
2019
Q3
$0 Hold
7
﹤0.01% 6850
2019
Q2
$0 Hold
7
﹤0.01% 6712
2019
Q1
$0 Hold
7
﹤0.01% 6580
2018
Q4
$0 Sell
7
-18
-72% -$1.52K ﹤0.01% 6690
2018
Q3
$4K Buy
25
+13
+108% +$1.92K ﹤0.01% 6158
2018
Q2
$2K Sell
12
-100
-89% -$15.1K ﹤0.01% 6211
2018
Q1
$28K Buy
112
+17
+18% +$4.79K ﹤0.01% 5737
2017
Q4
$27K Sell
95
-10
-10% -$3.81K ﹤0.01% 5716
2017
Q3
$43K Buy
105
+25
+31% +$13K ﹤0.01% 5522
2017
Q2
$48K Buy
80
+8
+11% +$4.68K ﹤0.01% 5398
2017
Q1
$45K Buy
72
+38
+112% +$13.5K ﹤0.01% 5479
2016
Q4
$7K Hold
34
﹤0.01% 5895
2016
Q3
$9K Hold
34
﹤0.01% 5789
2016
Q2
$10K Hold
34
﹤0.01% 5671
2016
Q1
$14K Sell
34
-7
-17% -$2.62K ﹤0.01% 5602
2015
Q4
$20K Buy
41
+4
+11% +$2.89K ﹤0.01% 5580
2015
Q3
$44K Sell
37
-10
-21% -$15.3K ﹤0.01% 5313
2015
Q2
$82K Buy
47
+6
+15% +$9.33K ﹤0.01% 5163
2015
Q1
$48K Buy
41
+3
+8% +$3.55K ﹤0.01% 5032
2014
Q4
$38K Sell
38
-22
-37% -$22K ﹤0.01% 5126
2014
Q3
$81K Hold
60
﹤0.01% 4743
2014
Q2
$102K Sell
60
-7
-10% -$13.3K ﹤0.01% 4672
2014
Q1
$151K Buy
67
+48
+253% +$123K ﹤0.01% 4466
2013
Q4
$39K Buy
19
+9
+90% +$19.4K ﹤0.01% 4824
2013
Q3
$30K Buy
+10
New +$17.1K ﹤0.01% 4839

Other funds holding VYNT

Wells Fargo's VYNT Position: Q2 2023 in Review

Wells Fargo sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 31 shares — an estimated $18 sold.

Wells Fargo first reported a position in VYNT in Q3 2013 and held it in 39 quarters. The position peaked at $151K in Q1 2014. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

  • Wells Fargo reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Wells Fargo sold 31 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $18.
  • Wells Fargo first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 39 quarters.
  • Wells Fargo's Vyant Bio, Inc. Common Stock position peaked at $151K in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.

Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.